Table 3B.
Outcome analysis: ICU admission
| Variable | 0 (N = 219) | 1 (N = 63) | Average marginal effect (AME) | p | Lower | Upper |
|---|---|---|---|---|---|---|
| CAC | 49% | 55% | 0.0385 | .495 | −0.0721 | 0.1491 |
| Age (years) | 51.450/62.100/76.700 | 56.500/67.300/73.850 | 0.0022 | .057 | −0.0001 | 0.0046 |
| Male sex | 65% | 76% | −0.0865 | .053 | −0.1741 | 0.0011 |
| Hypertension | 46% | 67% | 0.1458 | .001 | 0.0634 | 0.2282 |
| Diabetes | 21% | 25% | 0.0394 | .52 | −0.0804 | 0.1591 |
| Smoking | 14% | 25% | 0.1478 | .056 | −0.0038 | 0.2994 |
| Obesity | 20% | 20% | 0.0029 | .9647 | −0.1272 | 0.1330 |
| Dyslipidemia | 28% | 38% | 0.0844 | .052 | −0.0006 | 0.1693 |
| WBC × mm3 | 3.7/4.9/6.8 | 3.9/5.5/10.9 | 0.0107 | .079 | −0.0012 | 0.0226 |
| Creatinine (mg/dl) | 0.7200/0.8000/1.0700 | 0.7300/0.9100/1.2825 | −0.0033 | .705 | −0.0205 | 0.0138 |
| CRP admission (mg/L) | 17/55/89 | 58/100/160 | 0.0018 | <.001 | 0.0012 | 0.0025 |
| Procalcitonin | 0.0400/0.0600/0.1525 | 0.0975/0.2700/0.4825 | 0.0003 | .994 | −0.073 | 0.0736 |
| Saturation O2 | 93/96/97 | 88/92/95 | −0.0213 | .001 | −0.0333 | −0.0092 |
| HScTnI admission (ng/L) | 3/6/18 | 8/14/40 | 0 | .945 | −0.0007 | 0.0008 |
| consolidation | 14% | 25% | 0.1478 | .056 | −0.0038 | 0.2994 |
| GGO | 79% | 94% | 0.1836 | <.001 | 0.1008 | 0.2665 |
| Bilateral infiltration | 83% | 97% | 0.2077 | <.001 | 0.1248 | 0.2906 |
| Antibiotic use | 94% | 100% | 0.2293 | <.001 | 0.1749 | 0.2837 |
| Antiviral use | 35% | 38% | 0.0189 | .746 | −0.0954 | 0.1332 |
| Hydroxychloroquine | 35% | 18% | −0.134 | .001 | −0.2147 | −0.0533 |
| Corticosteroids | 53% | 79% | 0.1806 | <.001 | 0.0854 | 0.2759 |
| Tocilizumab | 5% | 7% | 0.0341 | .774 | −0.1988 | 0.267 |
| Plasma transfusion | 13% | 25% | 0.146 | .031 | 0.013 | 0.279 |
| d‐dimer >1000 | 10% | 18% | 0.1670 | .028 | 0.0180 | 0.3160 |
| Peak HScTnI 34–200 | 12% | 21% | 0.2030 | .0338 | 0.0155 | 0.3905 |
| Peak HScTnI >200 | 5% | 26% | 0.4470 | <.001 | 0.2468 | 0.6471 |
| Previous CAD | 9% | 13% | 0.0666 | .4275 | −0.0976 | 0.2311 |
| Chronic kidney disease | 8% | 14% | 0.116 | .2873 | −0.09765 | 0.3296 |
| Peripheral vasculopathy | 7% | 17% | 0.1878 | .09081 | −0.02986 | 0.4055 |
| Pulmonary hypertension | 0% | 2% | ||||
| Chronic broncopneumopathy | 4% | 8% | 0.1502 | .2977 | −0.1325 | 0.433 |
| Previous malignancy | 9% | 12% | 0.05042 | .6034 | −0.1398 | 0.2407 |
| Active malignancy | 10% | 8% | −0.02369 | .7462 | −0.1672 | 0.1198 |
| Multivariate analysis: Data are AME, p (p‐value), and lower and upper bound of the 95% confidence interval | ||||||
| Variable | AME | p | Lower | Upper |
|---|---|---|---|---|
| Antibiotics | 0.2554 | <.001 | 0.1979 | 0.3129 |
| Bilateral infiltrates | 0.1632 | .008 | 0.0426 | 0.2839 |
| Peak HScTnI 34–200 | 0.1788 | .031 | 0.0164 | 0.3412 |
| Peak HScTnI >200 | 0.3350 | .002 | 0.1273 | 0.5428 |
| Saturation O2 | −0.0147 | .030 | −0.0279 | −0.0014 |
Note: Data are percentages for categorical variables and I quartile/median/III quartile for continuous variables. The table also reports the results of the univariate models, as AME, p (p‐value), and lower and upper bound of the 95% confidence interval.
Abbreviations: CAC, coronary artery calcium; CAD, coronary artery disease; CRP, C‐reactive protein; GGO, ground‐glass opacification; HScTnI, high‐sensitivity cardiac troponin I; ICU, intensive care unit; WBC, white blood count.